163 related articles for article (PubMed ID: 21623673)
1. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
Gregersen T; Grønbæk H; Worsøe J; Schlageter V; Laurberg S; Krogh K
Scand J Gastroenterol; 2011 Jul; 46(7-8):895-902. PubMed ID: 21623673
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal transit times and motility in patients with cystic fibrosis.
Hedsund C; Gregersen T; Joensson IM; Olesen HV; Krogh K
Scand J Gastroenterol; 2012 Sep; 47(8-9):920-6. PubMed ID: 22746323
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
4. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
[TBL] [Abstract][Full Text] [Related]
5. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
6. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
7. Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans.
Falkén Y; Hellström PM; Sanger GJ; Dewit O; Dukes G; Grybäck P; Holst JJ; Näslund E
Neurogastroenterol Motil; 2010 Jun; 22(6):e192-200. PubMed ID: 20100281
[TBL] [Abstract][Full Text] [Related]
8. An open trial of octreotide long-acting release in the management of short bowel syndrome.
Nehra V; Camilleri M; Burton D; Oenning L; Kelly DG
Am J Gastroenterol; 2001 May; 96(5):1494-8. PubMed ID: 11374688
[TBL] [Abstract][Full Text] [Related]
9. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
10. Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans.
Bouras EP; Burton DD; Camilleri M; Stephens DA; Thomforde GM
Neurogastroenterol Motil; 2004 Dec; 16(6):729-35. PubMed ID: 15601422
[TBL] [Abstract][Full Text] [Related]
11. Circulating gastrointestinal hormone abnormalities in patients with severe idiopathic constipation.
van der Sijp JR; Kamm MA; Nightingale JM; Akkermans LM; Ghatei MA; Bloom SR; Jansen JB; Lennard-Jones JE
Am J Gastroenterol; 1998 Aug; 93(8):1351-6. PubMed ID: 9707064
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
13. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
14. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
15. Small doses of the unabsorbable substance polyethylene glycol 3350 accelerate oro-caecal transit, but slow gastric emptying in healthy subjects.
Coremans G; Vos R; Margaritis V; Ghoos Y; Janssens J
Dig Liver Dis; 2005 Feb; 37(2):97-101. PubMed ID: 15733521
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
Anthony L; Vinik AI
Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
[TBL] [Abstract][Full Text] [Related]
17. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Al-Efraij K; Aljama MA; Kennecke HF
Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
[TBL] [Abstract][Full Text] [Related]
18. Prokinetic effects of mirtazapine on gastrointestinal transit.
Yin J; Song J; Lei Y; Xu X; Chen JD
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G796-801. PubMed ID: 24627566
[TBL] [Abstract][Full Text] [Related]
19. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
Simonenko VB; Dulin PA; Makanin MA
Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
[TBL] [Abstract][Full Text] [Related]
20. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
